收费全文 | 145000篇 |
免费 | 10489篇 |
国内免费 | 667篇 |
耳鼻咽喉 | 1936篇 |
儿科学 | 3458篇 |
妇产科学 | 2175篇 |
基础医学 | 18318篇 |
口腔科学 | 3128篇 |
临床医学 | 15155篇 |
内科学 | 30594篇 |
皮肤病学 | 2139篇 |
神经病学 | 13474篇 |
特种医学 | 5825篇 |
外国民族医学 | 3篇 |
外科学 | 24209篇 |
综合类 | 1603篇 |
现状与发展 | 1篇 |
一般理论 | 228篇 |
预防医学 | 10606篇 |
眼科学 | 2967篇 |
药学 | 9560篇 |
1篇 | |
中国医学 | 217篇 |
肿瘤学 | 10559篇 |
2023年 | 1158篇 |
2022年 | 1959篇 |
2021年 | 4493篇 |
2020年 | 2457篇 |
2019年 | 3999篇 |
2018年 | 4704篇 |
2017年 | 3350篇 |
2016年 | 3565篇 |
2015年 | 4077篇 |
2014年 | 5797篇 |
2013年 | 7393篇 |
2012年 | 11224篇 |
2011年 | 11557篇 |
2010年 | 6392篇 |
2009年 | 5507篇 |
2008年 | 9478篇 |
2007年 | 9603篇 |
2006年 | 9252篇 |
2005年 | 9002篇 |
2004年 | 8031篇 |
2003年 | 7626篇 |
2002年 | 6836篇 |
2001年 | 1083篇 |
2000年 | 835篇 |
1999年 | 1125篇 |
1998年 | 1405篇 |
1997年 | 1058篇 |
1996年 | 895篇 |
1995年 | 880篇 |
1994年 | 726篇 |
1993年 | 690篇 |
1992年 | 604篇 |
1991年 | 585篇 |
1990年 | 535篇 |
1989年 | 550篇 |
1988年 | 504篇 |
1987年 | 480篇 |
1986年 | 474篇 |
1985年 | 501篇 |
1984年 | 548篇 |
1983年 | 478篇 |
1982年 | 546篇 |
1981年 | 503篇 |
1980年 | 445篇 |
1979年 | 288篇 |
1978年 | 329篇 |
1977年 | 274篇 |
1976年 | 210篇 |
1975年 | 221篇 |
1974年 | 213篇 |
Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献
Areas covered: Approximately 10–45% of patients undergoing head-and-neck cancers surgery develop SSIs. SSIs can lead to delayed wound healing, increased morbidity and mortality as well as costs. Consequently, SSIs need to be avoided where possible, as even the surgery itself impacts on patients’ subsequent activities and their quality of life, which is exacerbated by SSIs. Several risk factors for SSIs need to be considered to reduce future rates, and care is also needed in the selection and duration of antibiotic prophylaxis.
Expert commentary: Head and neck surgeons should give personalized care especially to patients at high risk of SSIs. Such patients include those who have had chemoradiotherapy and need reconstructive surgery, and patients from lower and middle-income countries and from poorer communities in high income countries, who often have high levels of co-morbidity because of resource constraints. 相似文献